Antacids Market Report

There is ageing geriatric population, which is a continuously growing segment, one of the best driving factors for the antacids market because this group of people is at the greatest risk of getting peptic ulcers and suffering from gastric reflux issues. Thus, along with the growing number of gastroesophageal reflux disease (GERD) sufferers, patients and caregivers increasingly rely on antacids in greatest numbers to eradicate and alleviate symptoms. Pharmaceutical companies are also focusing more towards coming up with better formation and improved versions that can cater to the rising demands of customers thus enhancing the growth of the market. Due to this, a number of scholar articles have been produced to provide information on the correlation of GERD disease in elderly people. WHO estimated that one of six people would be over 60 years of age by 2030. Gut an online magazine of the International Foundation for Gastrointestinal Disorders revealed that GERD affects approximately 18-28% of the population in the North America, 9-33% Middle East, 3-8% of the population in the East Asia, 9-26% in Europe, 12% in Australia and 23% in South America.

Pricing trends indicate that high raw material costs are impeding market expansion. Key raw materials like magnesium hydroxide and calcium carbonate have recently witnessed price increases. Home remedies for occasional heartburn and acidity, as well as changes in eating habits and lifestyle, are some of the other options posing a challenge to the global antacids industry. Furthermore, awareness regarding herbal treatments and traditional ways is one of the obstacles limiting market growth. According to research published in the journal Gut, young children who were taking medicines that reduced stomach acid exhibited signs of obesity. Prolonged use of acid-reducing medications alters gut bacteria, resulting in weight gain. Antacids market is also being threatened by an increase in restrictions imposed by governments all over globe. It is anticipated that the availability of antacid alternatives and a lack of knowledge of acidity symptoms will limit market growth. Furthermore, persons with specific medical disorders are more vulnerable to adverse effects that affect their health. For instance, the high salt content of antacids may cause issues with heart disease. Pregnant women are also advised not to use this bicarbonate-containing antacid. Another research released by Frontiers Media SA showed a connection between infant’s antacid use and bone fractures. If the use of this antacid increases, the dose will have a severe effect, limiting market expansion.

Partnerships and collaborations are essential in the antacid market to drive product innovation and increase market coverage. Businesses are teaming up to utilize one another's knowledge in creating, studying, and distributing antacid products, resulting in the creation of innovative and enhanced offerings. These partnerships also make it easier to access advanced technologies and regulatory knowledge, leading to faster introduction of innovative solutions to the market. For instance, in February 2022, GSK launched Haleon, an independent consumer healthcare firm. Additionally, Pfizer Inc., Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Bayer AG, Sanofi, Sun Pharmaceuticals Ltd., Reckitt Benckiser Group plc, Takeda Pharmaceutical Company Limited and Procter & Gamble are some of the prominent market players operating in the global antacids market.

The accessibility of cutting-edge pharmaceutical research facilities and the rising popularity of self-medication drive the industry in the United States. The market in the United States is expected to expand as a result of the growing prevalence of GERD due to lifestyle changes. Due to the increasing incidence of gastrointestinal diseases, antacid medication is expected to be in high demand in the United States. Antacids are the most often purchased over-the-counter product in the United States.  Prilosec OTC, Nexium 24 hours, Zantac 150 and Tums are some of the antacid products available in the nation. Product approval is a major factor driving market expansion. As per to a company announcement, Zydus Lifesciences acquired final permission from the US Food and Drug Administration (USFDA) to launch Famotidine tablets in the strengths of 20 mg and 40 mg in June 2022. The market is expected to grow significantly over the forecast period as a consequence of the aforementioned factors.